iTeos Therapeutics agrees to be acquired by Concentra Biosciences for $10.047/share plus CVR

iTeos Therapeutics, Inc.

Acquisition price: $10.047 per share cash plus one contingent value right (CVR).
CVR entitles holders to 100% of net cash above $475M and 80% of net proceeds from certain asset sales within 6 months.
Minimum net cash condition of $475M must be met; Concentra has no financing condition.
iTeos also terminated GSK collaboration, agreeing to pay $32M one-time termination payment.
Board unanimously recommends tender; support agreements cover ~0.6% of shares.

item 1.01item 5.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.